Evidence map›Paper›PMID 41785288›Full record

ArticlePloS one2026

Characterization of the TREM-1 signaling landscape in human neutrophils.

Frederic Ries, Matthias Klein, Nora Rogmann, Sophie Többen, Federico Marini, Florian Heidel, Markus P Radsak

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Frederic RiesDepartment of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Matthias KleinInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Nora RogmannDepartment of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Sophie TöbbenDepartment of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.ORCID https://orcid.org/0009-0008-7715-9665
Federico MariniResearch Center for Immunotherapy (FZI), Mainz, Germany.ORCID https://orcid.org/0000-0003-3252-7758
Florian HeidelDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
Markus P RadsakDepartment of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.ORCID https://orcid.org/0000-0002-3991-5721

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Triggering Receptor Expressed on Myeloid Cells (TREM)-1 is a member of the Immunoglobulin superfamily, and an activating receptor mainly expressed on myeloid cells. Beyond its role in acute and chronic inflammatory processes, TREM-1 is also involved in cancer emergence and progression probably by alteration of the tumor-associated neutrophils (TAN) and macrophages (TAM). Advanced information about the TREM-1 signaling cascade may reveal novel targets for treating inflammatory and cancer diseases. As many specific kinase inhibitors are approved for treating various diseases, targeting kinases being active after TREM-1 ligation serves as a promising approach. Therefore, we investigated the protein tyrosine kinome (PTK) and serine threonine kinome (STK) by kinome activity profiling of purified human neutrophils after TREM-1 activation. As TREM-1 interacts with Toll-like receptor (TLR) 4 signaling, we used TLR4-activation by LPS to define TREM-1 specific pathways. We found an increased kinome activity after receptor ligation and could predict individual kinases. To gain further insights into the signaling cascade, we additionally investigated the transcriptomic profile that made us available to link the kinome activity to the resulting transcriptomic profile. In sum, we revealed several signaling pathways being active after TREM-1 ligation that are associated with various biological processed and diseases. This study facilitates selecting kinase inhibitors for further validation with the aim of targeting TREM-1 signaling in various inflammatory or cancer disease conditions.

Indexed as

Membrane GlycoproteinsNeutrophilsReceptors, ImmunologicSignal TransductionTriggering Receptor Expressed on Myeloid Cells-1HumansLipopolysaccharidesToll-Like Receptor 4LipopolysaccharidesMembrane GlycoproteinsReceptors, ImmunologicToll-Like Receptor 4TREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1

Identifiers

PMID41785288
PMCPMC12962488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.